AP2015008670A0 - Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate - Google Patents
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamateInfo
- Publication number
- AP2015008670A0 AP2015008670A0 AP2015008670A AP2015008670A AP2015008670A0 AP 2015008670 A0 AP2015008670 A0 AP 2015008670A0 AP 2015008670 A AP2015008670 A AP 2015008670A AP 2015008670 A AP2015008670 A AP 2015008670A AP 2015008670 A0 AP2015008670 A0 AP 2015008670A0
- Authority
- AP
- ARIPO
- Prior art keywords
- methyl
- pyrimidino
- pyridino
- fluorobenzyl
- pyrazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2806895 | 2013-02-21 | ||
CA2807859A CA2807859A1 (en) | 2013-02-21 | 2013-02-21 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
PCT/EP2014/053096 WO2014128109A1 (en) | 2013-02-21 | 2014-02-18 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2015008670A0 true AP2015008670A0 (en) | 2015-08-31 |
Family
ID=50137643
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2015008670A AP2015008670A0 (en) | 2013-02-21 | 2014-02-18 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-B]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate |
Country Status (23)
Country | Link |
---|---|
US (5) | US20150376184A1 (ko) |
EP (2) | EP3760629A1 (ko) |
JP (1) | JP6386478B2 (ko) |
KR (1) | KR20150119871A (ko) |
CN (1) | CN105102457A (ko) |
AP (1) | AP2015008670A0 (ko) |
AU (1) | AU2014220801A1 (ko) |
BR (1) | BR112015019571A2 (ko) |
CA (1) | CA2901636A1 (ko) |
CL (1) | CL2015002304A1 (ko) |
CR (1) | CR20150422A (ko) |
CU (1) | CU20150092A7 (ko) |
DO (1) | DOP2015000199A (ko) |
EA (1) | EA201500852A1 (ko) |
HK (1) | HK1217488A1 (ko) |
IL (1) | IL240397A0 (ko) |
MX (1) | MX2015010725A (ko) |
NI (1) | NI201500110A (ko) |
PE (1) | PE20151590A1 (ko) |
PH (1) | PH12015501839A1 (ko) |
SG (1) | SG11201506211RA (ko) |
TN (1) | TN2015000361A1 (ko) |
WO (1) | WO2014128109A1 (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
CN104434845B (zh) * | 2014-11-12 | 2017-12-05 | 广东东阳光药业有限公司 | 一种包含利奥西呱的固体药物制剂 |
WO2016113415A1 (en) | 2015-01-16 | 2016-07-21 | Sandoz Ag | Process for the preparation of riociguat essentially free from genotoxic impurities |
KR20180002657A (ko) | 2015-05-06 | 2018-01-08 | 바이엘 파마 악티엔게젤샤프트 | 전신 경화증 (SSc)에 수반되는 수족지 궤양 (DU)의 치료를 위한 sGC 자극제, sGC 활성화제 단독 및 PDE5 억제제와의 조합물의 용도 |
CN113750102A (zh) | 2015-07-23 | 2021-12-07 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
CN108463224A (zh) | 2015-12-14 | 2018-08-28 | 铁木医药有限公司 | sGC刺激剂用于胃肠功能障碍治疗的应用 |
CN105596311A (zh) * | 2015-12-29 | 2016-05-25 | 郑州大明药物科技有限公司 | 一种利奥西呱口服固体制剂及其制备方法 |
WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
US20190381039A1 (en) | 2016-12-13 | 2019-12-19 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS |
EP3609883B1 (en) | 2017-04-11 | 2022-06-29 | Sunshine Lake Pharma Co., Ltd. | Fluorine-substituted indazole compounds and uses thereof |
EA202092680A1 (ru) | 2018-05-15 | 2021-04-13 | Байер Акциенгезельшафт | 1,3-тиазол-2-ил-замещенные бензамиды для лечения заболеваний, ассоциированных с сенситизацией нервных волокон |
US20210177846A1 (en) | 2018-07-11 | 2021-06-17 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS |
WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
CN111689961A (zh) * | 2020-06-01 | 2020-09-22 | 江苏华阳制药有限公司 | 一种利奧西呱的新晶型及其制备方法 |
WO2022147183A1 (en) * | 2020-12-30 | 2022-07-07 | Jubilant Pharma Holdings Inc. | Pharmaceutical extended release suspensions of riociguat |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
DK181190D0 (da) | 1990-07-30 | 1990-07-30 | Lundbeck & Co As H | 3-aryl-indol- eller 3-aryl-indazolderivater |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
CN1209809A (zh) | 1996-01-22 | 1999-03-03 | 藤泽药品工业株式会社 | 新化合物 |
HUP0001115A3 (en) | 1996-10-14 | 2001-06-28 | Bayer Ag | Heterocyclylmethyl-substituted pyrazol derivatives, process for their preparation and pharmaceuticals containing the same |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
SK287161B6 (sk) | 1997-11-12 | 2010-02-08 | Bayer Healthcare Ag | 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE19834045A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19846514A1 (de) | 1998-10-09 | 2000-04-20 | Bayer Ag | Neue Heterocyclyl-methyl-substituierte Pyrazole |
GB0002666D0 (en) | 2000-02-04 | 2000-03-29 | Univ London | Blockade of voltage dependent sodium channels |
DE10057754A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Sulfonamid-substituierte Pyrazolopyridinderivate |
DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
US6903089B1 (en) | 2000-11-22 | 2005-06-07 | Bayer Aktiengesellschaft | Lactam-substituted pyrazolopyridine derivatives |
AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
DE10122894A1 (de) | 2001-05-11 | 2002-11-14 | Bayer Ag | Neue Sulfonat-substituierte Pyrazolopyridinderivate |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
US7584505B2 (en) | 2001-10-16 | 2009-09-01 | Microsoft Corporation | Inspected secure communication protocol |
EP1448557A4 (en) | 2001-10-26 | 2005-02-02 | Univ Connecticut | HETEROINDANE: A NEW CLASS OF HIGH-ACTIVITY CANNABIMIMETIC LIGANDS |
WO2003076408A2 (en) | 2002-03-08 | 2003-09-18 | Abbott Laboratories | Indazole derivatives that are activators of soluble guanylate cyclase |
US6738631B1 (en) | 2002-05-06 | 2004-05-18 | Nokia, Inc. | Vision-guided model-based point-and-click interface for a wireless handheld device |
DE10220570A1 (de) * | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
DE10222550A1 (de) | 2002-05-17 | 2003-11-27 | Bayer Ag | Substituierte Benzyl-pyrazolopyridine |
DE10232571A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | 4-Aminosubstituierte Pyrimidinderivate |
DE10232572A1 (de) | 2002-07-18 | 2004-02-05 | Bayer Ag | Neue 2,5-disubstituierte Pyrimidinderivate |
DE10242941A1 (de) | 2002-09-16 | 2004-03-18 | Bayer Ag | Substituiertes Pyrazolderivat |
DE10244810A1 (de) | 2002-09-26 | 2004-04-08 | Bayer Ag | Neue Morpholin-überbrückte Indazolderivate |
EP1646382A4 (en) | 2003-06-30 | 2010-07-21 | Hif Bio Inc | COMPOUNDS, COMPOSITIONS AND METHODS |
TWI258478B (en) | 2003-10-31 | 2006-07-21 | Arena Pharm Inc | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
CN100355732C (zh) | 2003-11-03 | 2007-12-19 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
DE10351903A1 (de) | 2003-11-06 | 2005-06-09 | Bayer Healthcare Ag | Neue Kombination |
GB0403819D0 (en) | 2004-02-20 | 2004-03-24 | Merck Sharp & Dohme | New compounds |
US7514463B2 (en) | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
DE102005020468A1 (de) * | 2005-04-29 | 2006-11-02 | Albrecht Bäumer GmbH & Co.KG | Niederhalter für Maschinen |
DE102006021733A1 (de) | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
DE102006043443A1 (de) * | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
US20100210644A1 (en) | 2007-06-25 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Chemical compounds |
AR067762A1 (es) | 2007-07-31 | 2009-10-21 | Vertex Pharma | Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma |
US20120029083A1 (en) | 2007-11-13 | 2012-02-02 | Teva Pharmaceutical Industries, Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
KR20100113542A (ko) | 2008-01-01 | 2010-10-21 | 시플라 리미티드 | 보센탄, 그의 결정다형 형태 및 그의 염의 합성 방법 |
EP2262498A2 (en) | 2008-03-10 | 2010-12-22 | Vertex Pharmceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
DE102008030206A1 (de) * | 2008-06-25 | 2009-12-31 | Bayer Schering Pharma Aktiengesellschaft | 3-Cyanoalky- und 3-Hydroxyalkyl-Indole und ihre Verwendung |
DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
DE102009004245A1 (de) | 2009-01-09 | 2010-07-15 | Bayer Schering Pharma Aktiengesellschaft | Neue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung |
AR077898A1 (es) * | 2009-08-26 | 2011-09-28 | Nycomed Gmbh | Metilpirrolopirimidincarboxamidas |
DK2504334T3 (en) * | 2009-11-27 | 2014-12-08 | Bayer Ip Gmbh | PROCEDURE FOR PURIFICATION OF METHYL- {4,6-DIAMINO-2- [1- (2-FLUOROBENZYL) -1H-PYRAZOLO [3,4-B] PYRIDIN-3-YL] PYRIMIDIN-5-YL} METHYL CARBAMATE |
UY33041A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pharma Aktienegesellschaft | Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico |
UY33040A (es) * | 2009-11-27 | 2011-06-30 | Bayer Schering Pahrma Akitengesellschaft | Nuevas formas polimorfas de {4,6diamino-2-[1-(2-fluorobencil-1h-pirazol[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo |
RU2012129671A (ru) * | 2009-12-14 | 2014-01-27 | Байер Интеллектуэль Проперти Гмбх | НОВЫЕ СОЛЬВАТЫ МЕТИЛ (4, 6-ДИАМИНО-2-[1-(2-ФТОРБЕНЗИЛ)-1Н-ПИРАЗОЛО[3, 4-b]ПИРИДИН-3-ИЛ]ПИРИМИДИН-5-ИЛ)КАРБАМАТА |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
HUE025162T2 (en) * | 2010-05-26 | 2016-04-28 | Adverio Pharma Gmbh | Use of sGC stimulators, sGC activators alone or in combination with PDE5 inhibitors to treat systemic sclerosis (SSc). |
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
US9365574B2 (en) * | 2010-05-27 | 2016-06-14 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
MX2013000198A (es) * | 2010-07-09 | 2013-01-28 | Bayer Ip Gmbh | Pirimidinadas y triazinas condensadas y su uso. |
DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
DE102010040234A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 5-Flour-1H-pyrazolo[3,4-b]pyridin-3-carbonitril |
DE102010043380A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Benzyl-substituierte Carbamate und ihre Verwendung |
DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
EP2714660B1 (en) * | 2011-05-31 | 2018-09-26 | Theravance Biopharma R&D IP, LLC | Neprilysin inhibitors |
JP6054967B2 (ja) * | 2011-09-02 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アネレート化ピリミジンおよびその使用 |
WO2013076168A1 (de) | 2011-11-25 | 2013-05-30 | Bayer Pharma Aktiengesellschaft | Verfahren zur herstellung von substituierten 5-fluor-1h-pyrazolopyridinen |
DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
CN104327107A (zh) * | 2013-10-17 | 2015-02-04 | 广东东阳光药业有限公司 | 一种氟喹诺酮类抗菌药物的制备方法 |
US10414766B2 (en) * | 2015-12-15 | 2019-09-17 | Alembic Pharmaceuticals Limited | Polymorph of Riociguat and its process for the preparation |
EP3574905A1 (en) * | 2018-05-30 | 2019-12-04 | Adverio Pharma GmbH | Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group |
-
2014
- 2014-02-18 JP JP2015558419A patent/JP6386478B2/ja active Active
- 2014-02-18 SG SG11201506211RA patent/SG11201506211RA/en unknown
- 2014-02-18 CN CN201480009667.6A patent/CN105102457A/zh active Pending
- 2014-02-18 EP EP20185169.8A patent/EP3760629A1/en not_active Withdrawn
- 2014-02-18 WO PCT/EP2014/053096 patent/WO2014128109A1/en active Application Filing
- 2014-02-18 US US14/769,334 patent/US20150376184A1/en not_active Abandoned
- 2014-02-18 AP AP2015008670A patent/AP2015008670A0/xx unknown
- 2014-02-18 AU AU2014220801A patent/AU2014220801A1/en not_active Abandoned
- 2014-02-18 BR BR112015019571A patent/BR112015019571A2/pt not_active IP Right Cessation
- 2014-02-18 EA EA201500852A patent/EA201500852A1/ru unknown
- 2014-02-18 PE PE2015001788A patent/PE20151590A1/es not_active Application Discontinuation
- 2014-02-18 CA CA2901636A patent/CA2901636A1/en not_active Abandoned
- 2014-02-18 EP EP14705337.5A patent/EP2958914B1/en active Active
- 2014-02-18 MX MX2015010725A patent/MX2015010725A/es unknown
- 2014-02-18 KR KR1020157022555A patent/KR20150119871A/ko not_active Application Discontinuation
-
2015
- 2015-08-06 IL IL240397A patent/IL240397A0/en unknown
- 2015-08-17 CL CL2015002304A patent/CL2015002304A1/es unknown
- 2015-08-17 NI NI201500110A patent/NI201500110A/es unknown
- 2015-08-18 DO DO2015000199A patent/DOP2015000199A/es unknown
- 2015-08-18 CR CR20150422A patent/CR20150422A/es unknown
- 2015-08-20 CU CUP2015000092A patent/CU20150092A7/es unknown
- 2015-08-20 PH PH12015501839A patent/PH12015501839A1/en unknown
- 2015-08-21 TN TN2015000361A patent/TN2015000361A1/en unknown
-
2016
- 2016-05-13 HK HK16105474.6A patent/HK1217488A1/zh unknown
-
2017
- 2017-08-09 US US15/672,921 patent/US10087183B2/en active Active
-
2018
- 2018-08-31 US US16/119,671 patent/US10662188B2/en active Active
-
2020
- 2020-04-14 US US16/848,249 patent/US11203593B2/en active Active
-
2021
- 2021-11-15 US US17/526,129 patent/US20220073515A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2015002304A1 (es) | 2016-06-03 |
NI201500110A (es) | 2016-02-15 |
PE20151590A1 (es) | 2015-11-19 |
CA2901636A1 (en) | 2014-08-28 |
US10662188B2 (en) | 2020-05-26 |
EP2958914A1 (en) | 2015-12-30 |
US20200239469A1 (en) | 2020-07-30 |
TN2015000361A1 (en) | 2017-01-03 |
PH12015501839A1 (en) | 2015-11-09 |
KR20150119871A (ko) | 2015-10-26 |
US20170334910A1 (en) | 2017-11-23 |
EP2958914B1 (en) | 2020-07-15 |
MX2015010725A (es) | 2016-05-31 |
US10087183B2 (en) | 2018-10-02 |
DOP2015000199A (es) | 2015-11-15 |
BR112015019571A2 (pt) | 2017-07-18 |
US20150376184A1 (en) | 2015-12-31 |
WO2014128109A1 (en) | 2014-08-28 |
SG11201506211RA (en) | 2015-09-29 |
US20180370970A1 (en) | 2018-12-27 |
AU2014220801A1 (en) | 2015-09-10 |
JP2016509039A (ja) | 2016-03-24 |
EP3760629A1 (en) | 2021-01-06 |
EA201500852A1 (ru) | 2016-02-29 |
IL240397A0 (en) | 2015-09-24 |
CN105102457A (zh) | 2015-11-25 |
CU20150092A7 (es) | 2016-03-31 |
HK1217488A1 (zh) | 2017-01-13 |
JP6386478B2 (ja) | 2018-09-05 |
US20220073515A1 (en) | 2022-03-10 |
US11203593B2 (en) | 2021-12-21 |
CR20150422A (es) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217488A1 (zh) | -二氨基- -氟苄基 -吡唑并 吡啶- -基 嘧啶- -基}甲基氨基甲酸甲酯的形式 | |
IL241184A0 (en) | Naphthyridine derivatives and their use as antagonists of alpha-v-beta-6-integrins | |
ZA201507874B (en) | 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors | |
HK1190710A1 (zh) | 氟烷基取代的吡唑並吡啶及其用途 | |
ZA201409299B (en) | Risperidone or paliperidone implant formulation | |
HK1215575A1 (zh) | 吡咯並吡啶或吡唑並吡啶衍生物 | |
IL251164A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
ZA201409297B (en) | Paliperidone implant formulation | |
HK1223090A1 (zh) | -氮雜吲哚衍生物 | |
EP2970924A4 (en) | PHYTASEFORMULIERUNG | |
HK1225723A1 (zh) | 取代的咪唑並[1,2-a]吡啶甲酰胺及其用途 | |
HUE047855T2 (hu) | 3-etil-4-{3-izopropil-4-(4-(1-metil-1H-pirazol-4-il)-1H-imidazol-1-il)-1H-pirazolo[3,4-B|piridin-1-il}benzamid kristály alakja | |
IL233529A0 (en) | 1, 5-naphthyridine derivatives and malac inhibitors containing them | |
IL251166A0 (en) | Imidazo-[4,5-c]pyridine derivatives as inhibitors of ssao | |
HK1208029A1 (en) | Imidazopyridine derivatives | |
HK1214244A1 (zh) | 咪唑並吡啶衍生物 | |
TH1501004779A (th) | รูปแบบของเมทิล {4,6-ไดอะมิโน-2-[1-(2-ฟลูออโรเบนซิล)-1H-ไพราโซโล[3,4-b] ไพริดิโน-3-อิล]ไพริมิดิโน-5-อิล}เมทิลคาร์บาเมต | |
ITRM20120395A1 (it) | Dispositivo per la stimolazione di coppie di punti corporei. |